L-Dopa represents the mainstay of therapy of Parkinson's disease (PD), but its effectiveness is reduced with continued treatment and disease progression. Accordingly, there remains a need to explore novel treatment strategies to manage the signs and symptoms of the later disease stages. The aim of the study was to evaluate the efficacy and safety of adjunctive perampanel (PER) in patients with PD through a meta-analysis of existing trials.
Efficacy and safety of perampanel in Parkinson's disease. A systematic review with meta-analysis / Lattanzi, Simona; Grillo, Elisabetta; Brigo, Francesco; Silvestrini, Mauro. - In: JOURNAL OF NEUROLOGY. - ISSN 0340-5354. - STAMPA. - 265:4(2018), pp. 733-740. [10.1007/s00415-017-8681-y]
Efficacy and safety of perampanel in Parkinson's disease. A systematic review with meta-analysis
Lattanzi, Simona
Writing – Review & Editing
;Silvestrini, MauroSupervision
2018-01-01
Abstract
L-Dopa represents the mainstay of therapy of Parkinson's disease (PD), but its effectiveness is reduced with continued treatment and disease progression. Accordingly, there remains a need to explore novel treatment strategies to manage the signs and symptoms of the later disease stages. The aim of the study was to evaluate the efficacy and safety of adjunctive perampanel (PER) in patients with PD through a meta-analysis of existing trials.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
